Precipio Inc
Change company Symbol lookup
Select an option...
PRPO Precipio Inc
LFLY Leafly Holdings Inc
QNRX Quoin Pharmaceuticals Ltd
INDP Indaptus Therapeutics Inc
RNAZ Transcode Therapeutics Inc
NEOV NeoVolta Inc
SYBX Synlogic Inc
FIISO Financial Institutions Inc
KA Kineta Inc
TCS Container Store Group Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Health Care Providers & Services | Small Cap Value
Company profile

Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.

Closing Price
$5.60
Day's Change
-100.48 (-94.72%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.35
Day's Low
4.75
Volume
(Heavy Day)
Volume:
169,477

10-day average volume:
29,869
169,477

GM and mobility battery maker Posco Future M to invest more than $1 billion in complex that will make key battery material CAM

7:16 am ET June 2, 2023 (MarketWatch)
Print

General Motors Co. (GM) and mobility battery maker Posco Future M said Friday they are planning to expand the electric vehicle battery supply chain in North America with a new complex that will produce Cathode Active Material, or CAM, a key battery material that accounts for about 40% of the cost of a battery cell. Currently, most CAM and pCAM, a specifically engineered combination of processed raw materials necessary to produce CAM, is made in Asia. The new investment is expected to exceed $1 billion, the companies said in a joint statement. The CAM joint venture is expected to support production of about 360,000 Chevrolet, Cadillac, GMC, Buick and BrightDrop vehicles annually in the 2025-2030 timeframe in North America,. said the statement. "We started by establishing battery cell production in the U.S.," said Doug Parks, GM executive vice president, global product development, purchasing and supply chain. "From there, we have been working through the entire battery supply chain, all the way to raw material recovery. We're building higher levels of vertical integration, driving expanded investment and helping create jobs across North America." GM stock was up 1.3% premarket, but has fallen 1.8% in the year to date, while the S&P 500 has gained 10%.

-Ciara Linnane

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

	

(END) Dow Jones Newswires

June 02, 2023 07:16 ET (11:16 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.